PRLD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Prelude Therapeutics Inc (PRLD) is not a strong buy at the moment based on the investor's long-term strategy and beginner level. While the stock has potential upside based on analyst ratings and preclinical data, the lack of strong technical signals, weak financial performance, and absence of recent positive news or influential trading activity suggest that it is better to hold off on investing in this stock for now.
The MACD is below 0 and negatively contracting, indicating a bearish trend. RSI is neutral at 53.387, and moving averages are converging, suggesting no clear direction. Key support is at 2.917, with resistance at 3.581. The stock is currently trading near its pivot level of 3.249.
Analyst from Citizens raised the price target to $6 from $3, citing potential best-in-class selectivity and disease-modifying potential for preclinical JAK2V617F data.
No significant hedge fund or insider trading activity. Financial performance shows a decline in net income (-42.72% YoY) and EPS (-44.74% YoY). No recent news or congress trading data available.
In Q4 2025, revenue increased by 41.00% YoY to $5.64M, but net income dropped by 42.72% YoY to -$16.46M. EPS also declined by 44.74% YoY to -0.21. Gross margin remained at 100%.
Citizens maintains an Outperform rating and raised the price target to $6, citing meaningful upside potential.
